The Uromigos

Episode 392: ASCO GU 2025 - HIF Inhibition with Casdatifan in Refractory RCC 15.02.2025 30:09 ↓

Toni Choueiri discusses the updated data from different cohorts of this novel HIF inhibitor.

Episode 391: ASCO GU 2025 - KIM-1 Data from Checkmate 214 15.02.2025 23:28 ↓

Vincent Xu discusses this emerging RCC biomarker and data from the Checkmate 214 trial

Episode 390: ASCO GU 2025 - Pembro-based Doublets in Refractory RCC and COSMIC-313 OS Update 15.02.2025 30:03 ↓

Laurence Albiges joins the show to discuss novel combos in refractory RCC and an update of the Ipi/Nivo/Cabo COSMIC OS data

Episode 388: ASCO GU 2025 - FGF3 Inhibition with LOXO-435 in Urothelial Cancer 15.02.2025 25:28 ↓

Gopa Iyer from MSKCC joins the show to discuss his initial results from this phase 2 trial.

Episode 387: ASCO GU 2025 -Neoadjuvant Disitamab Vedotin + Toripalimab in HER2+ MIBC: updated efficacy and safety results 14.02.2025 27:07 ↓

Xinan Sheng. M.D., Professor in the Department of Genitourinary Oncology at Peking University Cancer Hospital &institute in Beijing, China joins us to discuss the update of this trial and impressive pCR rates.

Episode 389: ASCO GU 2025 - NIAGARA Pathologic CR Updates and Outcomes 14.02.2025 28:23 ↓

Matt Galsky joins the show to discuss pCR in NIAGARA and clinical implications.

Episode 386: ASCO GU 2025 - APRI Meta-analysis 13.02.2025 28:58 ↓

Tanya Dorff from City of Hope joins us to discuss clinical implications of these data and also comment on TALAPRO-2

Episode 385: ASCO GU 2025 - TALAPRO-2 13.02.2025 32:01 ↓

Neeraj Aggarwal joins Tom and Brian for an in-depth look at these important data

Episode 384: ASCO GU Preview 06.02.2025 35:23 ↓

Silke Gillessen joins Brian and Tom and they discuss what to look forward to in prostate, bladder and RCC at ASCO GU 2025.

Episode 383: A Neoantigen Vaccine Generates Anti-tumor Immunity in RCC 05.02.2025 33:11 ↓

David Braun joins the show to discuss his Nature paper on a personalized RCC vaccine

Episode 381: Molecular heterogeneity in urothelial carcinoma and determinants of clinical benefit to PD-L1 blockade 27.01.2025 40:05 ↓

Romain Banchereau joins the show to discuss and debate this Cancer Cell paper on molecular subtypes in urothelial cancer and implications for checkpoint blockade.

Episode 380: The Role of SBRT in RCC 13.01.2025 42:02 ↓

Shankar Siva joins the show to discuss the emerging role of stereotactic body radiotherapy (SBRT) in primary and metastatic RCC tumors.

Episode 378: 2025 Preview of Important GU Data 06.01.2025 41:42 ↓

Tanya Dorff from City of Hope joins Brian and Tom to review what to expect throughout 2025 and beyond in terms of clinically impactful data in prostate, renal and bladder cancer

Episode 375: Renal Cancer 2024 Highlights 23.12.2024 43:11 ↓

David McDermott (and his dog, Finn) join the show to review the top data from 2024 in RCC

Episode 376: Bladder Cancer 2024 Highlights 23.12.2024 25:37 ↓

Matt Galsky joins Brian and Tom to discuss the most impactful data in bladder cancer form the past year.

Episode 377: Prostate Cancer 2024 Highlights 23.12.2024 35:12 ↓

Silke Gilleson gives Tom and Brian 3 'gifts': Thomas Zilli (Radiation Oncology), Jochen Walz (Urology) and Ken Hermann (Nuclear Medicine) who discuss the 2024 prostate highlights from each of their unique perspectives.

Episode 374: Mechanisms of HIF Resistance 18.12.2024 34:37 ↓

Jim Brugarolas joins to discuss his talk from IKCS 2024 and the board topic of resistance to HIF inhibitors.

Episode 372: FDA Accelerated Approval Process 09.12.2024 31:30 ↓

Dan Suzman from FDA joins us to discuss the Accelerated Approval process, requirements, successes and challenges.

Episode 371: TROPICS-04 Results from ESMO Asia 07.12.2024 33:43 ↓

Jonathan Rosenberg joins Brian and Tom to discuss this important phase 3 trial and efficacy and toxicity signals.

Episode 370: Artificial Intelligence in Medical Oncology 02.12.2024 44:46 ↓

Jacob Kather joins Brian and Tom to discuss emerging AI applications in Oncology

Episode 369: Paper of the Month with Bishoy Faltas 25.11.2024 45:51 ↓

Bishoy joins us to discuss his work on extrachromosomal DNA in bladder cancer from his latest Nature publication

Episode 368: Radiomics in RCC: Live from IKCS 19.11.2024 37:00 ↓

Andrew Smith from St. Jude's joins us to discuss the emerging field of radiomics and shares his hopes and skepticism

Episode 367: Abiraterone vs AR inhibitors (Fanta vs Coke) in Prostate Cancer 11.11.2024 56:48 ↓

Chuck Ryan from MSKCC joins to talk about various aspects of AR inhibition in prostate cancer and relative benefits and risks.

Episode 366: ARPIs in Prostate Cancer - Are They Different? 04.11.2024 31:51 ↓

Chris Sweeney and Rob Jones join Brian and Tom to discuss the relative merits of different ARPIs in prostate cancer.

Episode 365: A Review of the Advanced Prostate Cancer Consensus Conference (APCCC) 28.10.2024 47:59 ↓

Episode 365: Silke Gillessen and Betrand Tombal join the show to discuss the APCCC meeting and recent publication.